Supplementary Figure S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Year: 2026
Type: supplementary-materials
Abstract: Supplementary Figure S1 | IPATHER trial design. aPatients could be pre-screened before or during induction treatment with chemotherapy and dual anti-HER2 blockade regimen. Patients who were HER2-positive and harbored a PIK3CA mutation, identified in archival or fresh tumor tissue samples (from primary breast, local recurrence, or metastatic lesions) or in ctDNA, qualified for the study. ctDNA, circulating tumor DNA; EOT, end of treatment; ER, estrogen receptor; HR, hormone receptor; MBC, metastatic breast cancer; PO, oral administration; PR, progesterone receptor; SC, subcutaneous.
Authors: Mafalda Oliveira, Eva Ciruelos, Guillermo Villacampa, Serafín Morales, Javier Salvador Bofill, Vanesa Quiroga, Joaquín Gavilá, Alexandra Cortegoso, Estela Vega, Fernando Henao, Sonia Servitja, Pablo Tolosa, Samyukta Chillara, Milana Bergamino, Fernando Salvador, Mariana Paes Dias, Juan M. Ferrero-Cafiero, Xavier Gonzalez Farre, Tomás Pascual, Cristina Saura
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7127657166